Wilmington, Delaware, Transparency Market Research Inc. , Dec. 16, 2024 (GLOBE NEWSWIRE) — The global Epidermal Growth Factors (EGFs) market (Marché des Facteurs de croissance épidermiques (EGF)) was valued at US$ 1.1 Bn in 2023 and is anticipated to expand at a CAGR of 11.3% from 2024 to 2034, reaching a valuation of over US$ 3.7 Bn by the end of 2034. The market is witnessing significant growth due to the increasing adoption of EGFs in wound healing, cancer therapies, skincare products, and regenerative medicine, fueled by technological advancements in biotechnology and biopharmaceuticals.
The surge in demand for anti-aging and skin rejuvenation products is a key factor driving the growth of the epidermal growth factors market. Additionally, rising investments in the biopharmaceutical sector, advancements in growth factor-based therapeutics, and increasing applications in autoimmune and degenerative disease treatments are propelling market expansion. Leading players such as Thermo Fisher Scientific, Johnson & Johnson, and Amgen Inc. are focusing on strategic acquisitions and innovative solutions to strengthen their foothold in this high-growth market. For instance, Thermo Fisher Scientific’s acquisition of CorEvitas in 2023 has bolstered its portfolio, enabling advanced research in chronic disease therapeutics.
Request a Detailed PDF Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86183
Expanding Applications in Skincare, Wound Healing, and Cancer Therapy Driving Growth
The growing popularity of growth factor-enriched skincare products and the increasing prevalence of chronic wounds and cancer have underscored the need for innovative therapeutic solutions. EGFs have demonstrated remarkable efficacy in accelerating wound healing by promoting cell proliferation, making them essential in tissue repair and regenerative medicine. The rising global demand for anti-aging and wrinkle-reducing products, particularly in regions like North America, Europe, and Asia Pacific, is further fueling growth in the epidermal growth factors market.
In oncology, the role of EGFs in targeted cancer therapies has gained prominence, with increasing use in treatments for various cancers, including lung, breast, and colorectal cancer. The development of novel epidermal growth factor receptor (EGFR) inhibitors has revolutionized cancer care, with several pharmaceutical giants such as AstraZeneca, Roche, and Novartis leading the way. Furthermore, EGFs are emerging as a critical tool in regenerative medicine, facilitating cellular regeneration and improving clinical outcomes in conditions like autoimmune disorders and degenerative diseases.
Request Customization to Get Tailored Insights for Your Business Needs: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86183
Key Market Drivers
- Rising Demand for Anti-aging Products
The global shift toward health-conscious living and self-care has increased the demand for anti-aging products. EGFs, with their ability to stimulate collagen production and improve skin elasticity, are now a preferred ingredient in luxury skincare formulations, driving significant revenue generation. - Advancements in Biopharmaceutical Research
Rapid advancements in biotechnology and growth factor-based therapeutics have expanded the clinical applications of EGFs, particularly in cancer therapy and autoimmune disease management. - Increasing Prevalence of Chronic Diseases
With the growing prevalence of chronic wounds, cancers, and degenerative diseases, EGFs have become indispensable in therapeutic applications, further propelling market demand. - Strategic Investments and Acquisitions
Major players in the industry are focusing on mergers and acquisitions to strengthen their market presence. For example, Thermo Fisher Scientific’s acquisition of CorEvitas in 2023 supports advanced research in EGF-related chronic disease management.
Recent Industry Trends
- Innovative Skincare Products: Companies such as Johnson & Johnson and AmorePacific have launched growth factor-enriched skincare products targeting the premium anti-aging market.
- Precision Oncology Advancements: AstraZeneca and Roche have introduced next-generation EGFR inhibitors that enhance treatment outcomes in non-small cell lung cancer (NSCLC) and other malignancies.
- Focus on Regenerative Medicine: EGFs are increasingly being adopted in clinical trials focusing on organ regeneration and tissue engineering, expanding their therapeutic potential.
- Regional Growth Trends: Markets in Asia Pacific and Latin America are witnessing robust growth due to increased spending on biopharmaceuticals and the rising prevalence of chronic illnesses.
Market Segmentation
Type of EGFs
- TGF-alpha
- Amphiregulin
- Epiregulin
- Betacellulin
- Others
Application
- Skincare Products
- Wound Healing
- Cancer Therapy
- Autoimmune Disorders
- Regenerative Medicine
- Others
End-user
- Hospitals
- Specialty Clinics
- Others (Research Laboratories, Cosmetic Clinics, etc.)
Regions Covered
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy This Premium Research Report Now to Get Detailed Analysis: https://www.transparencymarketresearch.com/checkout.php?rep_id=86183<ype=S
Competitive Landscape
The epidermal growth factors market is highly competitive, with key players engaging in strategic acquisitions, product launches, and collaborations to enhance their market position. Leading companies profiled in the market report include:
- Johnson & Johnson: Expanding its portfolio with innovative skincare and wound healing products.
- Amgen Inc.: Pioneering cancer therapies targeting EGFR pathways.
- Thermo Fisher Scientific: Strengthened its chronic disease research capabilities through the acquisition of CorEvitas.
- Novartis AG: Focused on next-generation EGFR inhibitors for cancer treatment.
- F. Hoffmann-La Roche AG: A leader in precision oncology, leveraging EGFR inhibitors for lung and colorectal cancer therapies.
Other prominent players include GSK plc, AstraZeneca plc, Bayer AG, AbbVie Inc., and Merck & Co., Inc., which continue to innovate and invest in EGF applications across skincare, regenerative medicine, and biopharmaceuticals.
Future Outlook
The Epidermal Growth Factors (EGFs) market is poised for robust growth, driven by expanding applications in skincare, wound healing, and cancer therapies. With continuous advancements in biotechnology and rising demand for anti-aging products, the market presents significant opportunities for innovation and revenue generation. Strategic investments by key players, coupled with the growing focus on precision medicine and regenerative therapies, will likely shape the future of the epidermal growth factors market.
Explore Latest Research Reports by Transparency Market Research:
- Oligonucleotides Market (Marché des Oligonucléotides): Projected to grow at a CAGR of 11.9% from 2024 to 2034 and reach more than US$ 13.1 Bn by the end of 2034
- Nano-biotechnology Market (Mercado de la nanobiotecnología): Projected to advance at a CAGR of 9.3% from 2024 to 2034 and reach more than US$ 421.5 Bn by the end of 2034
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
